David A. Siegel Milestone Pharmaceuticals Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.85 - $4.4 $32,490 - $50,160	11,400 Added 79.72%	25,700 $73,000
Q1 2023 May 15, 2023	SELL	$3.14 - $4.2 $109,272 - $146,160	-34,800 Reduced 70.88%	14,300 $56,000
Q4 2022 Feb 14, 2023	BUY	$3.53 - $9.5 $173,323 - $466,450	49,100 New	49,100 $194,000
Q3 2021 Nov 15, 2021	SELL	$5.28 - $6.29 $187,968 - $223,924	-35,600 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.22 - $6.11 $117,450 - $137,475	-22,500 Reduced 38.73%	35,600 $196,000
Q1 2021 May 17, 2021	BUY	$5.79 - $8.85 $33,582 - $51,330	5,800 Added 11.09%	58,100 $336,000
Q4 2020 Feb 16, 2021	BUY	$5.57 - $7.66 $291,311 - $400,618	52,300 New	52,300 $350,000
Q3 2020 Nov 16, 2020	SELL	$3.34 - $9.8 $69,806 - $204,820	-20,900 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.77 - $4.56 $36,993 - $95,303	20,900 New	20,900 $79,000

28.6M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $59.4M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.